Doaa Mashaly

Dr. Doaa Mashaly

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2025 in European Journal of Pediatrics
Verified
Journal Article
Closed access
PDF file
MAMohamed A. Aldemerdash
Mohamed A. Aldemerdash
MAMohammed Abdellatif
Mohammed Abdellatif
MRMerna Raafat Roshdy
Merna Raafat Roshdy
AZAsmaa Zakaria
Asmaa Zakaria
ABAhmed Bayoumi
Ahmed Bayoumi
NHNaema Hamouda
Naema Hamouda

11 November 2025 in Bioengineering
Verified
Journal Article
Open access
PDF file
MDMuhiddin Dervis
Muhiddin Dervis
AMAhmed Marey
Ahmed Marey
STShiva Toumaj
Shiva Toumaj
RQRuaa Mustafa Qafesha
Ruaa Mustafa Qafesha
DMDoaa Mashaly
Doaa Mashaly
MUMuhammad Umair
Muhammad Umair
Magnetic Particle Imaging (MPI) is a new type of tracer-based imaging that has great spatial and temporal resolution, does not require ionizing radiation, and can see deep into tissues by directly measuring the nonlinear magnetization response of superparamagnetic iron oxide nanoparticles (SPIONs). Unlike Magnetic Resonance Imaging (MRI) or Computed Tomography (CT), MPI has very high contrast and quantitative accuracy, which makes it perfect for use in dynamic cardiovascular applications. This study presents a full picture of the most recent changes in cardiac MPI, such as the physics behind Field-Free Point (FFP) and Field-Free Line (FFL) encoding, new ideas for tracer design, and important steps in the evolution of scanner hardware. We discuss the clinical relevance of cardiac MPI in visualizing myocardial perfusion, quantifying blood flow, and guiding real-time interventions. A hybrid imaging workflow, which improves anatomical detail and functional assessment, is utilized to explore the integration of MPI with complementary modalities, particularly MRI. By consolidating recent preclinical breakthroughs and highlighting the roadmap toward human-scale implementation, this article underscores the transformative potential of MPI in cardiac diagnostics and image-guided therapy.

29 May 2026 in Bioengineering
Verified
Journal Article
Open access
PDF file
STShiva Toumaj
Shiva Toumaj
AAAhmed Afifi
Ahmed Afifi
MDMuhiddin Dervis
Muhiddin Dervis
DMDoaa Mashaly
Doaa Mashaly
AAAbdallah Abudraz
Abdallah Abudraz
MUMuhammad Umair
Muhammad Umair
Background: Magnetic particle imaging (MPI) is an emerging, tracer-based modality that directly detects superparamagnetic iron oxide nanoparticles (SPIONs) with exceptional sensitivity, quantitative signal behavior, and full immunity to air–tissue susceptibility artifacts. These features make MPI particularly well-suited for pulmonary imaging, where traditional techniques such as computed tomography (CT), magnetic resonance imaging (MRI), and nuclear medicine-based ventilation/perfusion (V/Q) imaging are limited by radiation exposure, low contrast, and motion-related signal degradation. Objective: This review synthesizes the current state of MPI for lung imaging, with emphasis on its physical principles, tracer development, preclinical applications, and its potential role in assessing pulmonary perfusion, vascular integrity, inflammation, and therapeutic responses. Methods: A systematic evaluation of preclinical studies was performed across three major application domains: pulmonary perfusion mapping, cell tracking and therapeutic monitoring, and vascular injury and permeability assessment. Study designs, SPION formulations, MPI acquisition strategies, and validation methods, including histopathology, biodistribution, broncho-alveolar lavage fluid (BALF) analysis, and Evans Blue assays, were examined to characterize methodological consistency and imaging performance. Results: MPI consistently demonstrated high-contrast, quantitative visualization of pulmonary blood flow, endothelial barrier disruption, inflammatory signaling, and transplanted or inhaled cell populations. Tracer engineering played a critical role: macroaggregated albumin superparamagnetic iron oxide nanoparticles (MAA-SPIONs) enabled capillary-level perfusion mapping, LS-008 improved temporal resolution and vascular delineation, Synomag/Synomag-D allowed quantification of vascular leakage in acute and chronic lung injury, and vascular cell adhesion molecule-1 (VCAM-1)-targeted probes provided molecular-level assessment of inflammation. Hybrid MPI-CT and MPI-MRI approaches further enhanced anatomic localization and enabled accurate pulmonary blood volume (PBV) estimation. Across studies, MPI measurements showed strong agreement with established biological assays and remained free of the artifacts that limit CT and MRI in the lung. Conclusions: Preclinical evidence demonstrates that MPI is a robust, radiation-free, and quantitatively precise modality for functional and molecular lung imaging. Its ability to map perfusion, track therapeutic agents, and noninvasively quantify vascular permeability positions MPI as a promising future alternative or complement to CT, MRI, and nuclear medicine for pulmonary assessment. Continued tracer optimization, system scaling, and clinical validation are key steps toward translating MPI into routine clinical use.

17 February 2026 in Journal of Foot and Ankle Research
Verified
Journal Article
Open access
RQRuaa Mustafa Qafesha
Ruaa Mustafa Qafesha
HIHammam Anas Ishreiteh
Hammam Anas Ishreiteh
ANAdli Luay Nassourah
Adli Luay Nassourah
OTOmar Islam Tawil
Omar Islam Tawil
DMDoaa Mashaly
Doaa Mashaly
Background: Plantar fasciitis (PF) is a common cause of heel pain that affects the health‐related quality of life of many individuals and has various treatment options. Two effective interventions are corticosteroid (CS) injections and dextrose prolotherapy (DP). This study aimed to compare the efficacy and safety of DP and CS in patients with PF systematically. Methods: Relevant studies, including those comparing DP and CS for treating PF, were identified by searching electronic databases until August 2025. The visual analog scale (VAS) pain score, foot function index (FFI), and plantar fascia thickness (PFT) were compared between the groups in the short term (0.5–1 month) and mid‐term (3 months). Statistical analyses were performed via RevMan 4.5.1, and p < 0.05 was considered statistically significant. Results: Five RCTs and two cohort studies, with a total of 567 patients, were included in the meta‐analysis. The analysis revealed that at the short‐term follow‐up (1 month), corticosteroid injections were more effective at reducing the VAS pain scores than dextrose prolotherapy for general VAS score (MD = 1.85, 95% CI [0.05, 3.64], p = 0.04), the VAS score at the first step in the morning (MD = 1.26, 95% CI [0.49, 2.02], p = 0.001), and the VAS score for pain while walking (MD = 1.85, 95% CI [0.68, 3.02], p = 0.002). Similarly, at the short‐term follow‐up (1 month), the analysis revealed a significantly greater reduction in the FFI score (MD = 18.81, 95% CI [0.06, 37.55]) and PFT (MD = 0.26 mm, 95% CI [0.07, 0.45]) in the CS group than in the DP group. At 3 months, the analysis revealed a significant decrease in the FFI score ( p = 0.003) in the DP group compared with the CS group, whereas no significant difference was observed in the VAS scores or PFT. Conclusion: In patients with plantar fasciitis, CS injections had greater efficacy than DP did in the short term; however, their efficacy became similar in the mid‐term follow‐up, with DP outperforming CS in terms of foot function. Further trials with standardized protocols and long‐term follow‐ups are needed to address potential biases.